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High grade serous epithelial ovarian cancer (HG-SOC) is one of the most devastating gyne-
cological cancers affecting women worldwide, with a poor survival rate despite clinical
treatment advances. HG-SOC commonly metastasizes within the peritoneal cavity, primar-
ily to the mesothelial cells of the omentum, which regulate an extracellular matrix rich in
collagens type I, III, and IV along with laminin, vitronectin, and fibronectin. Cancer cells
depend on their ability to penetrate and invade secondary tissue sites to spread, however
a detailed understanding of the molecular mechanisms underlying these processes remain
largely unknown. Given the high metastatic potential of HG-SOC and the associated poor
clinical outcome, it is extremely important to identify the pathways and the components
of which that are responsible for the progression of this disease. In vitro methods of reca-
pitulating human disease processes are the critical first step in such investigations. In this
context, establishment of an in vitro “tumor-like” micro-environment, such as 3D culture,
to study early disease and metastasis of human HG-SOC is an important and highly insight-
ful method. In recent years, many such methods have been established to investigate the
adhesion and invasion of human ovarian cancer cell lines.The aim of this review is to sum-
marize recent developments in ovarian cancer culture systems and their use to investigate
clinically relevant findings concerning the key players in driving human HG-SOC.
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High grade serous epithelial ovarian cancer (HG-SOC) is a devas-
tating disease and the most lethal of the gynecological malignan-
cies. Typically treatment consists of surgical debulking, followed
by platinum/taxol chemotherapy regimens (1, 2). Treatment fails
in up to 70% of patients, and patients with platinum resistant dis-
ease have a median survival of 6–12 months (1, 3). Some success
has been observed in clinical trials for the palliative management
of ascites accumulation using targeted antibody treatment (4), and
while this symptom based therapy is clinically important, disease
modifying/halting treatments are lacking. Other treatments have
shown varied success, including those that target tumor angiogen-
esis such as bevacizumab alone or in combination with platinum
agents and gemcitabine. Many other approaches have been taken
including tyrosine kinase inhibitors, angiopoietin inhibitors, his-
tone deacetylase inhibition, and EGF receptor targeting (5). The
role of immune cells and interactions with tumor stroma are under
intense investigation and may improve the future prospects for
immunotherapy based regimes (5). However, response to treat-
ment varies between patients and therefore, the development
of personalized care through discovery of predictive molecu-
lar or protein markers becomes imperative for effective disease
treatment.
Modeling HG-SOC as closely as possible to human disease to
facilitate clinically relevant treatment testing is the “holy-grail”
in research. A plethora of immortalized ovarian cancer cells and
in vitro and in vivo model systems that utilize these cell lines
have been described. Early disease events are arguably the most
therapeutically relevant targets of preventative treatments and
here, we discuss recently used model systems to identify pathways
involved in the development of invasive malignancy.
ESTABLISHED EPITHELIAL OVARIAN CANCER CELL LINES AS
MODEL SYSTEMS: A CONTROVERSIAL CHOICE
High grade serous epithelial ovarian cancer has long been thought
to arise from the epithelial layer surrounding the ovary (6, 7).
However, studies point to a different site of origin, the secre-
tory cells of the fallopian tube fimbria. This highlights the lack
of understanding of the histogenesis and molecular signature of
this heterogeneous disease (8–14). Anglesio et al. suggested that
the biomarker and molecular signatures of ovarian cancer cell
lines may be a more accurate and relevant way of grouping “his-
totypes” over previously determined histological subtypes (15).
However, discrepancies between the molecular profile of ovarian
cancer cell lines and the tumor types they model have been iden-
tified. In fact, these profiles show more similarity between the cell
lines themselves, despite differing tissues of origin (8, 16). Further,
these reports have raised doubt on the use of a number highly
cited ovarian cancer cell lines as models of clinically relevant HG-
SOC, in particular A2780 and SKOV3 (8, 15). Cancer cell lines
derived from patients who have undergone treatment will repre-
sent a population of cells that is intrinsically different from that
of the original tumor due to the development of resistance. How-
ever, it has been suggested that cell lines derived from untreated
tumors are enriched for resistant cells with up-regulation of multi
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drug resistance associated genes via activation of stress responses
during the primary culture process (16).
Immortalized normal ovarian epithelial cells and normal fal-
lopian epithelial cells are increasingly being used to model early
stages of cancer development (10, 11, 17–21). While the use of
primary cancer cell cultures avoids issues associated with mul-
tiple passages (16), this is a labor intensive method, and dif-
ferences between individual primary cultures leading to lack of
reproducibility, may be a significant confounder. Immortalized
cell lines offer the advantage of increased stable survival over
longer periods in culture and can be manipulated to include many
genetic alterations to mimic the disease of interest. Studies using
immortalized cells derived from non-transformed normal human
fallopian epithelial secretory cells, along with the induction of rel-
evant genetic alterations, have been shown to successfully model
human high grade serous cancer biology (10, 11, 19). The use of
virally induced immortalization of cells is common; however this
may also induce unappreciated effects on tumor development and
virally induced tumor initiation is irrelevant to the pathogenesis
of ovarian cancer. Non-viral methods using shRNA technology
have also successfully targeted relevant genetic factors resulting in
transformed cells (11).
Along with the method of cell line derivation, site of origin,
and continuous passaging, culture conditions (monolayer, various
3D culture models, organ-like culture models) are also significant
effectors of the characteristics of established ovarian cancer cell
lines (8, 15, 16, 22). These issues are inherently difficult to address
and there is likely no ideal way to completely control for all these
changes. To date, particular HG-SOC cell lines have not been
reported as being more relevant to 3D culture compared to 2D
culture systems. SKOV3 and A2780 are the most commonly cited
but may not be the best representations of HG-SOC with their use
in 3D likely reflecting their popularity in 2D systems. Therefore
at this stage there are no specific criteria for cell line selection for
3D systems and progression from 2D to 3D experiments with the
same cell line can be a useful strategy. However, consistent use at a
low passage number, of an appropriate cell line to model HG-SOC
(via histological and molecular markers) is extremely important.
IN VITRO CULTURE MODEL SYSTEMS OF HGSEOC
2D VERSUS 3D CULTURE METHODS
Although it is well known that culturing cancer cell lines can
drastically alter their genetic characteristics over multiple passages
immortalized cancer cell lines remain the gold standard in cancer
research and pre-clinical drug testing (22). This is largely because
these cell lines display a consistent and relatively homogeneous
phenotype over long periods of time, notwithstanding reports of
minor side populations with cancer stem-like characteristics in
some cell lines (23, 24). Evidence is accumulating that culturing
these cells in 3D matrices is far more representative of disease
than traditional 2D systems, as they provide structurally similar
conditions for cell growth encompassing the ability to manipu-
late oxygen and growth factor/cytokine gradients as well as the
material properties of the matrix (22, 25–30).
Common methods for assessing ovarian cancer cell prolifera-
tion/migration/invasion have included 2D culture growth studies,
“scratch”wound healing assays, and penetration through transwell
inserts. Scratch wound assays are relatively easy to set up, and
very cheap to run and there are now many options for track-
ing and quantitating cell growth and migration, including the
MetaMorph™ and Incucyte™ real-time Imaging systems (31).
Migration assays through transwell inserts are more expensive
and do not allow for real-time monitoring. Microfluidic assays
have the advantage that cells can be grown in controlled chemo-
tactic gradients (31). However, these systems have not to date been
utilized widely for ovarian cancer cell culture studies. Cell spread-
ing assays, in which a plastic culture surface is coated with various
extracellular matrix (ECM) components (fibronectin or collagen
type I) and cells are allowed to spread under serum free conditions
for a short period of time, have been used to assess migration of
ovarian cancer cells (32). While these methods may provide some
useful information regarding the characteristics of certain cancer
cell lines and their responses to stimuli (drug treatment, signaling
molecules), they lack a 3D micro-environment to accurately mimic
pathophysiological conditions. 3D environments containing rele-
vant structural proteins (collagens, laminin, elastin) (Figure 1A),
as well as defined tissue organization appropriate to site of tumor
growth in vivo, are important considerations for recapitulating
tumor cell behavior (Figure 1B).
Spread of ovarian cancer cells is complex with cells respond-
ing to stimuli from neighboring cells and ECM components and
their ability to invade connective tissue is crucial for successful
metastasis. In the absence of a requirement for ECM interactions
and matrix degradation, 2D systems primarily evaluate the motil-
ity of cells, rather than a true invasive barrier removal (29). Care
must also be taken when interpreting results based on incomplete
3D representations of a bona fide tumor/metastatic site ECM. For
example, only a partial understanding of the involvement of pro-
teases/MMPs in the spread and invasion of ovarian cancer cells
can be drawn from experiments using matrices that lack structural
properties of a relevant ECM. For example, matrigel is substan-
tially less cross-linked and differs in overall composition compared
to many tissues (29, 31, 33).
Omental models have been used, in which a primary culture of
fibroblasts is grown in 2D with a confluent layer of mesothelial cells
grown on top before fluorescently labeled ovarian cancer calls are
seeded on a final layer to form a “mock” peritoneal environment.
Invasion is typically measured by fluorescent microscopy after the
cell layers are cultured in transwell inserts placed over growth
promoting media. (26, 34–36). These models provide a more accu-
rate representation of the tissue structure encountered by tumor
cells, by supplying a barrier to test “metastatic” invasion of cells
in presence of other cells such as fibroblasts that are important
to disease processes. However, primary tumor development and
the “metastatic cascade” are highly complex processes, and the 2D
platforms that are currently used do not typify pathways involved,
likely contributing to the unsuccessful translation of findings into
in vivo systems and eventual failure of many treatments under
clinical trial (37).
NATURAL VERSUS SYNTHETIC 3D PLATFORMS
The importance of recapitulating tumor ECM in model systems
was highlighted by Infanger and others in their review (25). These
authors stated that interactions between tumor cells and their
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FIGURE 1 | (A) Schematic representation of the structure and components of the common peritoneal site of ovarian cancer metastasis. (B) Schematic
representation of a cluster of adherent ovarian cancer cells invading, proliferating, and destroying basement membrane ECM tissue architecture.
surrounding micro-environment are as pivotal to tumorigenic-
ity as oncogenic mutation (25). Normal homeostatic process and
tissue structural properties control the dormancy required after
malignant transformation of epithelial cells and when these path-
ways fail, along with the presence of certain genetic mutations,
cells grow uncontrollably and tumors develop (25). Currently,
there is a definite lack of studies that evaluate the combined
effect of cell–cell, cell–ECM interactions as well as biochemical,
biomechanical, and the specific processes that occur during the
metastatic processes of ovarian cancer (25, 38).
Hydrogels, such as Matrigel, are commonly used for
in vitro studies of ovarian cancer cell growth and invasion
(29, 32, 39). Other substrates such as collagen gels (40),
polyhydroxyethylmethacrylate coated plastics (22), algimatrix,
and geltrex are also used to model ECM (16). Natural alter-
natives include human amniotic membranes (HAM) and chick
chorioallantoic membranes (CAM). 3D culture systems incorpo-
rating amniotic membranes have been used to assess the spreading
and invasive capacities of ovarian cancer cells. These offer the
advantage of a physiologically relevant tissue barrier for assess-
ment of cell behavior (41–43). Limitations of these materials are
the batch to batch variation, presence of confounding growth fac-
tors and other biological components whose effects on culturing
experiments are not well known (25, 44). Other non-biological
considerations in these model systems, which to date have been
largely ignored, are the tissue structural properties as well as
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gradients of oxygen tension and effects from external physical
stimuli (compression, shear stress) (25, 41).
Semi-synthetic matrices such as polyethylene glycol (PEG),
hyaluronan, alginate-based, and peptide-based (Puramatrix™)
hydrogels are amenable to experimental determination of matrix
stiffness and integration of different binding sites and protease
cleavage sites (31, 45). Matrix stiffness has been shown to influ-
ence endothelial cell behavior independently of matrix molecular
composition, highlighting the relevance of matrix material prop-
erties in tumor modeling (46). PEG based hydrogels have been
used to investigate the role of proteases in the migration of fibrob-
lasts (47) and more recently to investigate cell–ECM interactions
and drug resistance of epithelial ovarian cancer cells (48).
Semi-synthetic or synthetic matrices offer the greatest levels
of experimental reproducibility due to the control that investi-
gators have in the makeup of the ECM. The study by Loessner
et al. is, to date, the most relevant study using a synthetic 3D scaf-
fold to comprehensively investigate ovarian cancer cell growth and
response to drugs in an anisotropic biomimetic hydrogel (48). This
method enables combination of designed binding sites, protease
substrates, other proteins including growth factors and an easily
adjustable matrix stiffness. Cells seeded uniformly in the liquid
scaffold precursor are exposed to similar levels of biomechanical
and biochemical stimuli in all directions (48).
While these models are highly relevant, the addition of other
cell types found in the cancer micro-environment (stromal cells,
immune cells) would make these models more complete. The
immune response has been shown to be clinically relevant in ovar-
ian cancer. Traditionally, immune–cancer cell interactions have
been studied in 2D cultures by the addition of immune compo-
nents or immune stimulatory factors. The establishment of a phys-
iologically relevant tumor micro-environment would enable all
cells present (cancer, stromal, immune) to phenotypically resem-
ble those found in disease (49–52). This would create a unique
and powerful in vitro situation for testing the effects of differ-
ent immune components and inflammatory responses relevant to
disease. For example, TNF-β is known to effect ECM stability, and
could therefore influence the capacity of tumor cells to migrate
and invade (53). A biologically relevant in vitro representation of
a tumor is also central for accurately testing drug efficacy, as the
interaction of different cell types contributes to the drug response
(54). Various 3D models (spheroid cultures, scaffold based 3D cul-
tures, organotypic cultures) would be amenable to the addition of
immune factors/cytokines, and although not yet in development,
3D co-culture of many cell types found in ovarian cancer including
immune cells should be possible (55, 56).
Heterotypic culture to simulate the micro-environment of
ovarian cancer has been shown to be a promising and repre-
sentative method for investigating stromal–epithelial interactions
during disease (57). It has been suggested that modeling ovarian
cancer by using 3D cultures of fallopian tube secretory epithe-
lial cells would be more relevant to early stage HG-SOC (58).
Combining synthetic matrices, in heterotypic culture with the
relevant cells that drive the initiation processes of disease to inves-
tigate potential therapeutic targets, would be ideal. A collaborative
effort between the NIH, FDA, and the Defense Advanced Research
Projects Agency has been instigated to develop and refine methods
for functional organ microphysiological systems aimed at drug
screening (59). These may also have potential for use in cancer
biology. For example, a human liver-like model has been devel-
oped to study breast cancer metastases (60). It is possible that such
models may, in the future, be adapted to investigate metastases
to the liver in ovarian cancer. Table 1 summarizes some of the
factors to consider when choosing a method to model cancer cell
growth.
3D modeling of early stage ovarian cancer, which the afore-
mentioned systems aim to achieve, may be the most relevant for
identifying potential targets for disease modifying therapies. The
second stage of disease involves the spread of ovarian cancer cells
from the primary tumor into the peritoneal space. Experiments
to capture the behavior of ovarian cancer cells during metas-
tasis focus on anchorage-independent models of cell migration
(68–71). Multicellular aggregate, or spheroid formation is criti-
cal for shedding of cancer cells from the primary tumor, and it
has recently been shown that the culture of ovarian cancer cells as
spheroids in a biomimetic ECM, recapitulates the metastatic niche
(72). Further, the biomechanical environment of the peritoneal
space plays an important role on cancer cell behavior and spread,
and so incorporation of physiological fluid mechanics are appro-
priate in these systems (41, 69). While the development of oxygen
tension gradients limits the size of the multicellular spheroids in
culture; it mimics the structure of solid tumors and the potential
development of necrotic cores (73, 74). This representation of the
physiological micro-environment is relevant and appropriate for
the screening of drugs, as penetration into the tumor/spheroid is
very different to 2D systems and consequently, the response will
also be very different (75). A recent study by Jaeger et al. describes
the development of a 3D culture system incorporating an oxygen
permeable polymer and micro pillars, to mimic gas delivery via
vessels (76). This system offers the potential of larger growth of
organotypic models and more realistically represents vascularized
tumors in vivo.
Tissue chips are a relatively new area of research aimed at incor-
porating as many components as possible to recapitulate the living
tissue and study biological responses to many factors in concert
(77, 78). Tissue chips allow the modeling of organ systems in a
highly functional and controlled manner. They can incorporate
many components relevant to tumor biology such as various 3D
matrix components and hydrogels. These systems have the poten-
tial as tools for measuring metastatic potential, response to various
growth stimulators or inhibitors, immune interactions, and drug
responses. However, optimization of parameters such as endpoint
data collection is still required in order to use these systems for
complex tumor modeling (77, 78).
CONCLUSION AND FUTURE PERSPECTIVES
Many advances have been made in recent years in the development
of representative 3D models to mimic ovarian cancer relevant to
human HG-SOC. However, these systems are still limited and
none to date combine all factors, biomechanical, and biologi-
cal, to create a complete experimental culture system. This is
compounded by recent controversy regarding the molecular char-
acterization of HG-SOC cell lines, with several that are commonly
used for research, being shown to be non-representative of this
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Table 1 | Summary of factors contributing to the choice of model system for ovarian cancer cell culture.
Natural/
synthetic
Control of ECM
composition
Relevance to
in vivo tumor
Comments/reference
COMPONENT/SYSTEM
Human amniotic membrane (HAM) Natural Low Medium Physiologically relevant/provides ECM barrier/batch to batch
variation high (42)
Chick chorioallantoic membrane (CAM) Natural Low Medium Physiologically relevant/provides ECM barrier/batch to batch
variation high (43)
Collagen gel (acid extracted type 1
collagen from rat tail)
Synthetic Medium Low Variable ECM stiffness/invasion assessment (binding
sites/matrix interaction) (61, 62)
Matrigel (derived from mouse EHS cell
secretions; laminin, collagen IV,
enactin, various growth factors)
Synthetic Medium Low Widely used (migration and invasion)/batch variation
high/irrelevant matrix composition/properties (29, 31, 33)
Alginate/peptide-based (inert
polysaccharide, β-d-mannuronic acid,
α-l-guluronic acid, calcium ions)
Synthetic High Medium Variable ECM stiffness/defined components/binding
sites/matrix interaction (63, 64)
PEG (various cross-linked polyethylene
glycol hydrogels) coasted plastics
Synthetic High Medium Variable ECM stiffness/defined components/binding
sites/matrix interaction/enzymatically degradable (31, 65)
Heterotypic/organotypic culture Synthetic High High Relevant micro-environment/cell interaction/combine with
synthetic ECM (64, 66)
Spheroid culture Synthetic High Medium Biologically relevant/cell–cell interactions/combine with
synthetic ECM (31, 58, 67)
grade of ovarian cancer. It has become clear that when modeling
the micro-environment, it is particularly important to create an
ECM that closely mimics that relevant to ovarian cancer, and so
considerations of the origin of the cell line are important. For
example, an ECM relevant to a primary tumor derived cell line
may be different from that of a cell line derived from ascites. Like-
wise, generation of an appropriate ECM for early disease modeling
may have different requirements for epithelial cells derived from
the fallopian tube to those derived from the ovarian surface. Only
through a comprehensive understanding of physiological tumor
behavior will it be possible to identify key players in tumor progres-
sion, whether these are ECM proteins (MMPs, TIMPs), immune
regulators or cytokines or upstream genetic changes in the cancer
cells themselves.
While the sophisticated 3D culture models developed in the last
few years have circumvented many problems associated with tradi-
tional methods, the use of these systems is still in its infancy in part
due to the complex nature, cost, and specialized equipment that is
often required. Thus these methods are not yet amenable for high-
throughput experimentation and pre-clinical testing. However,
technological progress in the coming years will hopefully reduce
these limitations and see the widespread use of high-throughput
screening using 3D culture systems that accurately recapitulate the
tumor micro-environment.
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